

FOR IMMEDIATE RELEASE

June 13, 2017

## **Dentsu Announces Its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail, a Developer of Blood Testing Techniques for the Early Detection of Cancer in the United States**

Dentsu Inc. (Tokyo: 4324; ISIN: JP3551520004; President & CEO: Toshihiro Yamamoto; Head Office: Tokyo; Capital: 74,609.81 million yen) announced today that Dentsu Ventures Global Fund I (hereinafter "Dentsu Ventures"), the Company's corporate venture capital fund, has made an investment in Grail, Inc. (Head Office: Menlo Park; CEO: Jeff Huber; hereinafter "Grail"), a developer of blood testing techniques for the early detection of cancer located in the United States.

Grail, a life science company whose mission is the early detection of cancer, utilizes proprietary sequencing (DNA sequence information reading) technologies, large-scale clinical trials and cutting-edge computer science and data science in an effort to develop and verify blood testing techniques for the early detection of cancer, when it can be cured. To this end, Grail has raised more than US\$900 million of necessary funding through a Series B financing round.

Dentsu Ventures is participating in the Series B financing round and plans to support Grail's partnership strategy in Japan. The Dentsu Group will establish alliances between clients and partner companies to encourage the practical application of Grail technologies in Japan. In the future, we also want to contribute to the adoption of testing aimed at the early detection of cancer and increased screening rates.

Dentsu Ventures is a fund established in April 2015 to realize open innovation across the Dentsu Group through collaborations and investments in start-up companies. The total amount of this fund has been increased from the existing ¥5 billion to ¥10 billion to expand these activities. We will continue to invest globally, and going forward, we plan to increase investments in the Asia-Pacific region, including Japan, as well as in the European region. We will also enhance our staff to support investees and further strengthen our joint business development structure with investees.

Profiles of Grail and Dentsu Ventures are provided below:

### Profile of Grail

Company Name: Grail, Inc.  
 Location: Menlo Park, California, U.S.A.  
 Representative: Jeff Huber, CEO  
 Line of Business: Development of blood testing techniques for the early detection of cancer  
 URL: <https://grail.com/>

### Profile of Dentsu Ventures

Name: Dentsu Ventures Global Fund I  
 Total Fund Capital: ¥10 billion  
 Date of Establishment: April 2015  
 Period of Operation: Ten-year period from April 2015 until March 2025  
 Investment Regions: Global investments with a focus on the U.S.A., Europe, Japan and Asia  
 Investment Stages: Balanced, wide-ranging investments with the focus on seed and early stage investments, but also including mid-stage and later-stage investments  
 Investment Areas: (1) Areas that can change the marketing and communication business in a broad sense  
 (2) New areas other than the above that have a high potential for innovation  
 URL: <http://dentsu-v.com/>

#####

### Contacts:

Media-related enquiries: Shusaku Kannan  
 Managing Director, Corporate Communications Division  
 Telephone: (813) 6216-8042  
 E-mail: [s.kannan@dentsu.co.jp](mailto:s.kannan@dentsu.co.jp)

Investment-related enquiries: Dentsu Ventures  
 E-mail: [info@dentsu-v.com](mailto:info@dentsu-v.com)